Richard Lowenthal

You need that medical benefit, that product differentiation to be able to compete against generics.

We also actually focus very much on the consumer and the patient caregiver.

And we have a copay program where our copay program actually can provide people with this disease who have commercial insurance with NEFI at a zero copay price.

So the price to the consumer is actually much less for NEFI than the generic auto injectors, which don't.

have the ability to provide a copay assistance.

So our average copay price is actually less than generic auto injector.

Yes, certainly.

Yeah, so of the entire current prescription market, now this is not necessarily the epidemiology of the disease, but the prescriptions being given out on an annual basis, about 50% are in adults and 50% of the prescriptions are pediatric children under 17 and under.

Our initial approval was for both adults and pediatric patients who were 30 kilograms or greater.

So there's not typically an age differentiation in this disease.

Epinephrine is dosed by weight.

So for 30 kilograms and above, they would take a two milligram dose.

Earlier this year, we got the one milligram intranasal epinephrine dose approved, which is for children 15 to less than 30 kilograms.

The children in that population, the one milligram dose that got approved earlier this year, it's roughly 24% of the market, of the prescription market today.

And we're seeing that market share in that part of the market growing quite well.

um and then and then of course we are also working on a dose we call it our baby dose but it's a dose for uh children that are 7.5 kilograms to 15 kilograms so that's approximately six months of age to a small four-year-old or a you know three-year-old um at the upper end um and we're we're also working on that and hope to have that approved um sometime late next year

Yes, well, we're still dealing with, of course, we're about a year into the launch and we have, we have relatively good coverage.

We have about ninety three percent of insurers that will cover.

58% are approving NEFI prescriptions without any prior authorization or other paperwork.

So it's simply send a prescription to the pharmacy and it's automatically filled.